Monday, 5 October 2015

DNX-2401 virotherapy plus PD1 antibody trial

Many of you probably already saw this on Al's news blast, but I wanted to post it here too:  a new phase 2 trial will be testing DNAtrix's DNX-2401 virotherapy with Merck's PD-1 antibody pembrolizumab (Keytruda).

http://www.businesswire.com/news/home/20151001005478/en/Merck-DNAtrix-Announce-Phase-2-Immuno-Oncology-Collaboration#.VhMY6vlVikp

This will be the second trial to combine a PD-1 antibody with a second immunotherapy (the other is Duke's trial combining their CMV-targeted dendritic cell vaccine with nivolumab, plus pre-conditioning of the vaccination site with tetanus/diptheria toxoid.

https://www.clinicaltrials.gov/ct2/show/NCT02529072

These are just the sorts of combinations we need!

No comments:

Post a Comment